SG11202011317PA - A process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom - Google Patents
A process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefromInfo
- Publication number
- SG11202011317PA SG11202011317PA SG11202011317PA SG11202011317PA SG11202011317PA SG 11202011317P A SG11202011317P A SG 11202011317PA SG 11202011317P A SG11202011317P A SG 11202011317PA SG 11202011317P A SG11202011317P A SG 11202011317PA SG 11202011317P A SG11202011317P A SG 11202011317PA
- Authority
- SG
- Singapore
- Prior art keywords
- arylalkylsulfanyl
- pyrimidines
- chiral
- hetero
- obtainable therefrom
- Prior art date
Links
- 125000005842 heteroatom Chemical group 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 230000000707 stereoselective effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1807898.0A GB201807898D0 (en) | 2018-05-15 | 2018-05-15 | New processes and products with increased chiral purity |
PCT/EP2019/062530 WO2019219771A1 (en) | 2018-05-15 | 2019-05-15 | A process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202011317PA true SG11202011317PA (en) | 2020-12-30 |
Family
ID=62623275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202011317PA SG11202011317PA (en) | 2018-05-15 | 2019-05-15 | A process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom |
Country Status (12)
Country | Link |
---|---|
US (3) | US11542281B2 (en) |
EP (1) | EP3793981A1 (en) |
JP (1) | JP7225379B2 (en) |
KR (1) | KR20210014646A (en) |
AU (1) | AU2019270348B2 (en) |
CA (1) | CA3099865A1 (en) |
GB (1) | GB201807898D0 (en) |
IL (1) | IL278644B2 (en) |
MX (1) | MX2020012108A (en) |
SG (1) | SG11202011317PA (en) |
WO (1) | WO2019219771A1 (en) |
ZA (1) | ZA202007101B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202006849D0 (en) | 2020-05-08 | 2020-06-24 | Kancera Ab | New use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA56992C2 (en) * | 1995-05-08 | 2003-06-16 | Фармація Енд Апджон Компані | a- pyrimidine-thioalkyl substituted and a- pyrimidine-oxo-alkyl substituted compounds |
SE9802729D0 (en) | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
JP2013010750A (en) | 2011-06-02 | 2013-01-17 | Taisho Pharmaceutical Co Ltd | Medicine containing two-pyridone compound |
JP2015231988A (en) | 2014-05-12 | 2015-12-24 | 大正製薬株式会社 | 2- pyridone compound |
-
2018
- 2018-05-15 GB GBGB1807898.0A patent/GB201807898D0/en not_active Ceased
-
2019
- 2019-05-15 SG SG11202011317PA patent/SG11202011317PA/en unknown
- 2019-05-15 KR KR1020207035250A patent/KR20210014646A/en not_active Application Discontinuation
- 2019-05-15 WO PCT/EP2019/062530 patent/WO2019219771A1/en unknown
- 2019-05-15 JP JP2021514480A patent/JP7225379B2/en active Active
- 2019-05-15 MX MX2020012108A patent/MX2020012108A/en unknown
- 2019-05-15 CA CA3099865A patent/CA3099865A1/en active Pending
- 2019-05-15 AU AU2019270348A patent/AU2019270348B2/en active Active
- 2019-05-15 EP EP19726334.6A patent/EP3793981A1/en active Pending
- 2019-05-15 US US17/055,172 patent/US11542281B2/en active Active
- 2019-05-15 IL IL278644A patent/IL278644B2/en unknown
-
2020
- 2020-11-13 ZA ZA2020/07101A patent/ZA202007101B/en unknown
-
2022
- 2022-10-14 US US17/966,294 patent/US11691988B2/en active Active
-
2023
- 2023-05-19 US US18/199,899 patent/US20230322807A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2020012108A (en) | 2021-02-18 |
US11542281B2 (en) | 2023-01-03 |
US20210188873A1 (en) | 2021-06-24 |
ZA202007101B (en) | 2023-05-31 |
AU2019270348B2 (en) | 2024-01-18 |
IL278644B1 (en) | 2023-11-01 |
US20230322807A1 (en) | 2023-10-12 |
JP7225379B2 (en) | 2023-02-20 |
WO2019219771A1 (en) | 2019-11-21 |
KR20210014646A (en) | 2021-02-09 |
EP3793981A1 (en) | 2021-03-24 |
AU2019270348A1 (en) | 2020-12-03 |
IL278644A (en) | 2021-01-31 |
CA3099865A1 (en) | 2019-11-21 |
CN112218853A (en) | 2021-01-12 |
US20230068240A1 (en) | 2023-03-02 |
IL278644B2 (en) | 2024-03-01 |
GB201807898D0 (en) | 2018-06-27 |
JP2021523950A (en) | 2021-09-09 |
US11691988B2 (en) | 2023-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276917A (en) | Process for the preparation of elobixibat | |
PT3594199T (en) | Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof | |
SG11202108238VA (en) | Process for the preparation of methionine | |
ZA202101214B (en) | Process and intermediates for the preparation of bilastine | |
AU2016248025B2 (en) | Polymorphs of AFATINIB and its salts and process for the preparation of quinazolinyl derivatives | |
EP3728241A4 (en) | Process for the preparation of opicapone and intermediates thereof | |
EP3717456A4 (en) | Process for the preparation of roxadustat and its intermediates | |
EP3986870A4 (en) | A novel crystalline form of olaparib and a process for preparing the same | |
ZA202007101B (en) | A process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom | |
LT3765440T (en) | Process for the preparation of n-alkyl-nitratoethylnitramines | |
IL271974A (en) | Novel intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same | |
EP3837239A4 (en) | Process for the preparation of solriamfetol and salt thereof | |
PL3737685T3 (en) | Process for the preparation of crisaborole and its intermediates | |
SI3620452T1 (en) | Process for the preparation of lenvatinib | |
EP3877361C0 (en) | Process for the preparation of arylsulfonylpropenenitriles | |
ZA201907515B (en) | Process for the preparation of pirlindole enantiomers and its salts | |
GB2555866B (en) | A novel crystalline form of epocholeone, a process for its preparation and use the same | |
IL290214A (en) | Continuous process for preparing the crystalline form ii of sotagliflozin | |
IL290215A (en) | Process for preparing the crystalline form ii of sotagliflozin | |
IL268103A (en) | Process for the preparation of chiral pyrollidine-2-yl- methanol derivatives | |
IL287228A (en) | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives | |
IL287230A (en) | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives | |
ZA202102159B (en) | Process for the preparation of a flavouring | |
HUP1800278A2 (en) | Process for the preparation of boc-linagliptin | |
HUE056997T2 (en) | Process for the preparation of pirlindole enantiomers and its salts |